Oncotarget

Clinical Research Papers:

11C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma

Katharina Lückerath _, Constantin Lapa, Christa Albert, Ken Herrmann, Gerhard Jörg, Samuel Samnick, Herrmann Einsele, Stefan Knop and Andreas K. Buck

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:8418-8429. https://doi.org/10.18632/oncotarget.3053

Metrics: PDF 801 views  |   HTML 1069 views  |   ?  


Abstract

Katharina Lückerath1, Constantin Lapa1,*, Christa Albert1, Ken Herrmann1, Gerhard Jörg1, Samuel Samnick1, Herrmann Einsele2, Stefan Knop2, Andreas K. Buck1

1University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg, Germany

2University Hospital Wuerzburg, Department of Internal Medicine II, Division of Hematology and Oncology, Wuerzburg, Germany

*These authors have contributed equally to this work

Correspondence to:

Katharina Lueckerath, e-mail: Lueckerath_K@ukw.de

Keywords: Multiple Myeloma, 11C-Methionine-PET, treatment response, molecular imaging

Received: November 26, 2014     Accepted: January 06, 2015     Published: January 20, 2015

ABSTRACT

Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers 11C-Methionine (paraprotein-biosynthesis) and 18F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138+ plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM.1S tumors underwent MET- and FDG-μPET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30–79% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET- but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3053